Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer
Condition(s):Breast CancerLast Updated:September 21, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Breast CancerLast Updated:September 21, 2023Recruiting
Condition(s):Healthy MenLast Updated:February 28, 2024Active, not recruiting
Condition(s):Breast CancerLast Updated:January 26, 2023Completed
Condition(s):Similarity of Pharmacokinetics and SafetyLast Updated:July 11, 2023Completed
Condition(s):Breast CancerLast Updated:February 22, 2023Active, not recruiting
Condition(s):Metastatic Breast Cancer; HER2-positive Breast CancerLast Updated:February 15, 2024Recruiting
Condition(s):Prostate CancerLast Updated:September 18, 2015Terminated
Condition(s):Esophageal CarcinomaLast Updated:July 1, 2020Completed
Condition(s):Breast CancerLast Updated:May 3, 2021Completed
Condition(s):HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer PatientsLast Updated:January 22, 2024Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.